Aarti Drugs Ltd
NSE:AARTIDRUGS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
321.75
545.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Aarti Drugs Ltd
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,450 full-time employees. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. The company also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,450 full-time employees. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. The company also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
Revenue Growth: Revenue for Q2 FY '26 rose 9% year-on-year to INR 652.9 crores, driven by strong export demand compensating for a soft domestic market.
Margin Recovery: EBITDA margin expanded by 150 basis points to 12.9%, and PAT margin improved by 110 basis points to 6.9%, reflecting cost efficiencies and improved product mix.
Backward Integration: The new Sayakha facility began commercial operations and is expected to fully meet captive demand by end of FY '26, supporting long-term margin and supply chain stability.
API and Formulations: API export volumes grew over 30% YoY in Q2, offsetting flat domestic API demand; formulation revenues grew 26% YoY in Q2, mostly from exports.
Guidance: For H2 FY '26, management expects high single-digit value growth; FY '27 targeted for 15% to 20% revenue growth and 15% EBITDA margin run rate by end of the year.
CapEx and Debt: CapEx guidance for FY '26 is INR 150–200 crores; total debt reduced to INR 571 crores with a record low debt-to-equity ratio of 0.39.
